The following information appeared on, Reuters.com
In a recent July 12, 2021, Rueters article by Trisha Roy and Caroline Humer, the cost and coverage of a new Alzheimer’s medication is brought to light.
The U.S. government on Monday started a review process for national Medicare cover-age of Biogen Inc’s (BIBB.O) Alzheimer’s drug, Aduhelm, that was recently approved by the country’s health regulator.
